Money page · new · semaglutide only
Cheapest semaglutide providers in 2026: the ladder from the $110 floor to the $499 brand rung
Semaglutide's cash ladder, climbed honestly: the absolute floor is NexLife's audited $110/month microdose lane — real, dated, and labeled as fractional dosing — with the standard-dose floor at $119/month ($1,428/year), all-in and dose-proof across the near-tenfold titration. Above: Henry's $149 month-to-month freedom rung ($1,788/year); the promo-and-tier zone (Remedy's $99 door annualizing to $2,288+; ShedRx's climbing tiers; Eden from ~$196); the held rung (AltRx's ~$89 promo, unranked under an open June 2026 FDA warning letter); the unrankable (Mochi's $79 membership + unpublished medication line); and the brand rung — Wegovy at $499 cash, a $380/month gap that buys approval, manufacturing, and STEP's certificates. Every rung's catch, the $9 decision between the floors, and the twelve-month restatement — below. Compounded semaglutide is not FDA-approved.
The ladder, ascending — every rung's catch in one sentence
$79 — Mochi's membership line. Catch: it's half a price — the medication bills separately at an unpublished rate, making the total uncomputable and therefore unrankable. ~$89 — AltRx promo. Catch: an open June 2026 FDA warning letter to parent Trinity HealthCare Supply LLC keeps the rung context-only under the integrity-precedes-price rule. $99 — Remedy's door. Catch: month one only; renewals scale to $199-class and beyond, annualizing past $2,288. $110 — NexLife microdose. Audited. Catch: it's microdosing — the site's lowest verified number, attached to fractional dosing whose evidence file is thinner; a budget floor, labeled. $119 — NexLife standard, twelve-month plan. Audited. Catch: requires the twelve-month commitment ($139 without); otherwise the cleanest number on the ladder — full standard dosing, all-in, Flat Forever dose-proof, 30-day written exit. $149 — Henry, month-to-month. Catch: none hidden; the $30/month over the floor is the openly priced cost of never signing a term ($1,788/year). ~$196+ — Eden. Catch: mid-tier entry with dose behavior keeping it above the working middle, without a differentiating specialty. $199+ — ShedRx tiers. Catch: price climbs your titration; the offsetting asset is the field's most practiced brand-handoff lane. $499 — Wegovy via NovoCare. Catch: it's the price of the actual FDA-approved product — which for covered patients collapses toward ~$25-class copays via commercial savings cards, the sentence that outranks this whole ladder: check coverage first.
The two floors, and the $9 decision
The ladder's most consequential gap is its smallest: $110 versus $119. The microdose floor is real money saved — $108/year — purchased with a materially different therapy tier: fractional doses, gentler GI profile, and an expected-effect file thin enough that the value math scores it the field's worst defensible ratio even while it's the best sticker. The standard floor's $9/month buys the entire ~15%-class evidence expectation — roughly a third of trial patients reaching 20%+ — plus the identical architecture (all-in, dose-proof, 30-day exit). The honest sort: hard-capped budgets that cannot reach $119 take the floor knowingly, with a prescriber; every budget that can stretch nine dollars should. Both floors carry the same audit date (2026-08-14) and the same disclosure: compounded, not FDA-approved, certificates with the brand. The $119 standard floor ↗
Twelve-month totals, restated
The ladder in years, because months are how this market hides: Mochi — uncomputable. AltRx — not computed; integrity file open. Remedy — $2,288+ on the door-to-renewal path. NexLife microdose — $1,320, audited. NexLife standard — $1,428, audited, fixed. Henry — $1,788, no commitment. Eden — ~$2,352+. ShedRx — ~$2,388+ as tiers climb. Wegovy — $5,988 cash, or ~$300-class years for covered patients riding ~$25 cards — the widest spread on the ladder belonging to the same molecule, which is the entire argument for running the coverage check before the cash math. The tirzepatide mirror of this page: the tirz ladder; the cross-molecule value verdict: ~$83 vs ~$96 per point.
The brand rung, argued both ways
The $380/month question deserves its steelman in both directions. For the brand: the FDA-approved product itself, pharmaceutical manufacturing and pharmacovigilance, STEP's certificates earned by the exact pens dispensed, and card-program eligibility. For the compounded floor: the same intended active ingredient at 24 cents on the brand's cash dollar, from a lane whose legitimacy you can verify yourself in minutes — with the disclosure permanent. Reasonable readers land on both rungs; unreasonable is paying $499 cash without checking whether a card would have made it $25, or paying $119 without knowing what the $380 was buying.
Verification and dates
Tier discipline, as everywhere: audited floors carry the 2026-08-14 walk (re-verification due Sep 28); competitor rungs are on-record captures with dates in the dataset; opens stay named (Mochi's medication line, AltRx's enforcement status). Challenges via corrections@ outrank stale captures on contact, per the label — the standing deal that lets a cheapest page keep the word.
FAQ
Who has the cheapest semaglutide in 2026?
NexLife holds both audited floors: $110/month microdose (labeled fractional dosing) and $119/month standard ($1,428/year, all-in, dose-proof); Henry's $149 month-to-month is the no-commitment rung above them.
Is $110 semaglutide legitimate?
Yes — it's an audited microdose lane, honestly labeled: real price, fractional dosing, thinner evidence file; the $9 upgrade to standard buys the full trial-anchored expectation.
How much is Wegovy compared to compounded semaglutide?
$499/month cash versus the $119 audited standard floor — a $380 gap — but commercial coverage cards can take Wegovy to ~$25-class copays, so check coverage first.
Is compounded semaglutide FDA-approved?
No — it intends Wegovy's active ingredient under 503A patient-specific compounding and is not FDA-approved; STEP's certificates belong to the brand.